Development of a nanotechnology-based approach for capturing and detecting nucleic acids by using flow cytometry
Metadatos
Mostrar el registro completo del ítemAutor
Robles Remacho, Agustín; Luque González, Angélica; Cano Cortes, María Victoria; López Delgado, Francisco Javier; Guardia Monteagudo, Juan José; Fara, Mario A.; Sánchez Martín, Rosario María; Díaz Mochón, Juan JoséEditorial
Elsevier
Materia
Nucleic acid testing (NAT) Fluorescence-activated cell sorting (FACS) Nanotechnology Dynamic chemical labeling (DCL) Peptide nucleic acid (PNA) KRAS point Mutation
Fecha
2021-05-01Referencia bibliográfica
Agustín Robles-Remacho, M. Angélica Luque-González, Roberto A. González-Casín, M. Victoria Cano-Cortés, F. Javier Lopez-Delgado, Juan J. Guardia-Monteagudo, Mario Antonio Fara, Rosario M. Sánchez-Martín, Juan José Díaz-Mochón, Development of a nanotechnology-based approach for capturing and detecting nucleic acids by using flow cytometry, Talanta, 226, 2021, 122092, ISSN 0039-9140, https://doi.org/10.1016/j.talanta.2021.122092.
Patrocinador
This research was supported by the Spanish Ministry of Economy and Competitiveness (grant number BIO2016-80519). The authors are members of the NANOCARE network (RED2018-102469-T) funded by the STATE INVESTIGATION AGENCY. ARR thanks the Spanish Ministry of Education for PhD funding (scholarship FPU15/06418). FJ Lopez Delgado thanks the Spanish Ministry of Economy and Competitiveness for the Torres Quevedo fellowship (PTQ-16- 08597). These studies were approved and supported by DestiNA Genomics Ltd. Schemes in Figs. 1 and 4–6 have been partially created using BioRender.com.Resumen
Nucleic acid-based molecular diagnosis has gained special importance for the detection and early diagnosis of genetic diseases as well as for the control of infectious disease outbreaks. The development of systems that allow for the detection and analysis of nucleic acids in a low-cost and easy-to-use way is of great importance. In this context, we present a combination of a nanotechnology-based approach with the already validated dynamic chemical labeling (DCL) technology, capable of reading nucleic acids with single-base resolution. This system allows for the detection of biotinylated molecular products followed by simple detection using a standard flow cytometer, a widely used platform in clinical and molecular laboratories, and therefore, is easy to implement. This proof-of-concept assay has been developed to detect mutations in KRAS codon 12, as these mutations are highly important in cancer development and cancer treatments.